Rigorous Clinical Trials: The ongoing Phase 3 trials are being run according to FDA and industry standards that ensure the integrity of all reported results. Mr. Barry succeeds Remi Barbier, the Company's Chairman, President and CEO, who resigned from the Company and the Board. Mr. Barbier will remain employed by the Company until September 13, 2024 in a nonexecutive capacity, without duties or responsibilities. Mr. Barry said that in addition to the leadership changes, the Board has added Pierre Gravier as ...

Mr. Capper continued, "With today's announcement, Kim is expanding her area of responsibility to include marketing and international commercial operations, where we will continue to benefit from her guidance. I look forward to working alongside of Kim and the rest of the MIMEDX team as we continue the process of building MIMEDX into a world class MedTech company." MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-hea ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Anthony Petrone - Mizuho Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Good afternoon and thank you for ...

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET Exhibit 99.1 MIMEDX Announces First Quarter 2024 Operating and Financial Results MARIETTA, Ga., April 30, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company"), today announced operating and financial results for the first quarter 2024. Recent ...

For the Quarterly Period Ended March 31, 2024 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Florida 26-2792552 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1775 West Oak Commons Ct NE Marietta, GA 30062 (Address of principal executive offices) (Zip Code) (770) 651-9100 (Registrant's telephone number, including area code) ☐ TRA ...

MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions. Commenting on this agreement, Joseph H. Capper, MIMEDX Chief Executive Officer, stated, "We are excited to announ ...

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ:MDXG) ("MIMEDX" or the "Company") today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value creation. In connection with these appointments, the Board of Directors unanimously a ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2023 Results Conference Call February 28, 2024 4:30 PM ET Company Participants Matt Notarianni - Head of Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig Hallum Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright Anthony Petrone - Mizuho John Vandermosten - Zacks Operator Greetings, and welcome to the MiMedx Group Inc. Fourth Quarter and Full Ye ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

Exhibit 99.1 MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., February 28, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Comp ...